These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8886461)

  • 1. Interaction of chemotherapy and biological response modifiers in the treatment of melanoma.
    Anderson CM; Buzaid AC; Grimm EA
    Cancer Treat Res; 1996; 87():357-80. PubMed ID: 8886461
    [No Abstract]   [Full Text] [Related]  

  • 2. New applications of cancer immunotherapy.
    Agarwala SS
    Semin Oncol; 2002 Jun; 29(3 Suppl 7):1-4. PubMed ID: 12068381
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biological response modifiers in the treatment disseminated melanoma].
    Akimov MA; Gershanovich ML
    Vopr Onkol; 2002; 48(2):172-8. PubMed ID: 12227064
    [No Abstract]   [Full Text] [Related]  

  • 4. Histamine as an adjunct to immunotherapy.
    Naredi P
    Semin Oncol; 2002 Jun; 29(3 Suppl 7):31-4. PubMed ID: 12068386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.
    Khayat D; Coeffic D
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():238-47. PubMed ID: 10895160
    [No Abstract]   [Full Text] [Related]  

  • 6. The rational development of biological response modifiers.
    Talmadge JE
    Biotherapy; 1992; 4(3):177-8. PubMed ID: 1599800
    [No Abstract]   [Full Text] [Related]  

  • 7. New approaches to the systemic treatment of melanoma.
    Chowdhury S; Vaughan MM; Gore ME
    Cancer Treat Rev; 1999 Oct; 25(5):259-70. PubMed ID: 10544070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
    Fiorentino B; Di Stefano P; Giuliani C; Amatetti C; Tinari N; Natoli C; Garufi C; Iacobelli S
    Br J Cancer; 1992 Nov; 66(5):981-3. PubMed ID: 1419647
    [No Abstract]   [Full Text] [Related]  

  • 9. Autoimmunity and immunotherapy for cancer.
    Koon H; Atkins M
    N Engl J Med; 2006 Feb; 354(7):758-60. PubMed ID: 16481646
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of biological response modifiers in malignant melanoma.
    Lens MB
    Expert Opin Biol Ther; 2003 Dec; 3(8):1225-31. PubMed ID: 14640948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological response modifiers in melanoma.
    Bridgewater JA; Gore ME
    Br Med Bull; 1995 Jul; 51(3):656-77. PubMed ID: 7552087
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
    Keilholz U; Scheibenbogen C; Brossart P; Möhler T; Tilgen W; Hunstein W
    Recent Results Cancer Res; 1995; 139():383-90. PubMed ID: 7597305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological monitoring and clinical trials of biological response modifiers.
    Baseler MW; Urba WJ
    Cancer Chemother Biol Response Modif; 1991; 12():231-50. PubMed ID: 1931445
    [No Abstract]   [Full Text] [Related]  

  • 15. Immune checkpoint blockade and interferon-α in melanoma.
    Rafique I; Kirkwood JM; Tarhini AA
    Semin Oncol; 2015 Jun; 42(3):436-47. PubMed ID: 25965362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
    Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
    Eton O; Legha SS; Bedikian AY; Lee JJ; Buzaid AC; Hodges C; Ring SE; Papadopoulos NE; Plager C; East MJ; Zhan F; Benjamin RS
    J Clin Oncol; 2002 Apr; 20(8):2045-52. PubMed ID: 11956264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy of melanoma: a critical review of current concepts and future strategies.
    Riker AI; Radfar S; Liu S; Wang Y; Khong HT
    Expert Opin Biol Ther; 2007 Mar; 7(3):345-58. PubMed ID: 17309326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Node positive melanoma--a positive note?
    Kelly J; Kerin MJ
    Surgeon; 2012 Apr; 10(2):63-4. PubMed ID: 22385525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.